Royce & Associates LP bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 22,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,308,000.
Other institutional investors have also recently bought and sold shares of the company. Landmark Wealth Management LLC bought a new position in Gilead Sciences in the 1st quarter worth $30,000. FSB Premier Wealth Management Inc. bought a new position in Gilead Sciences in the 4th quarter worth $28,000. Joseph P. Lucia & Associates LLC bought a new position in Gilead Sciences in the 1st quarter worth $25,000. Capital Advisors Ltd. LLC raised its holdings in Gilead Sciences by 127.6% in the 4th quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 250 shares during the period. Finally, TFO TDC LLC bought a new position in Gilead Sciences in the 1st quarter worth $27,000. Institutional investors own 80.16% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating on the stock in a research report on Monday, May 16th. BMO Capital Markets assumed coverage on shares of Gilead Sciences in a research report on Tuesday, June 7th. They issued a “hold” rating and a $63.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 price target on the stock. SVB Leerink assumed coverage on shares of Gilead Sciences in a research report on Monday, May 23rd. They issued a “market perform” rating and a $68.00 price target on the stock. Finally, StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $72.07.
Gilead Sciences Trading Down 1.3 %
Gilead Sciences Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 4.78%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 89.02%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.